At a glance
ClinicalIndex Comparison RecordN/ACompleted· 115 enrolled
Drug / intervention
Zenith TX2® TAA Endovascular Graftdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zenith TX2® TAA Endovascular Graft Post-approval Study
In Brief
A clinical study evaluating Zenith TX2® TAA Endovascular Graft for Descending Thoracic Aortic Aneurysm. Completed, enrolled 115 participants across 25 sites in 2 countries.
Detailed Summary
The Zenith TX2® Post-market Approval Study is a clinical trial approved by US FDA to further study the safety and effectiveness of the Zenith TX2® TAA Endovascular Graft in the treatment of thoracic aortic aneurysms.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDescending Thoracic Aortic Aneurysm
CountriesCanada, United States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartJul 2009
Primary CompletionFeb 2020
Study CompletionMar 2020
TodayJul 2026
First PostedDec 23, 2008
Enrollment StartJul 10, 2009
Primary CompletionFeb 14, 2020
Study CompletionMar 23, 2020
TodayJul 2, 2026
Enrollment to primary: 10.6 yearsPosted 17.5 years ago
Interventions
Zenith TX2® TAA Endovascular Graftdevice
Endovascular treatment with the study device